Last updated: August 6, 2025
Introduction
Patent JP2019052184, titled "Method for Producing a Pharmaceutical Composition," exemplifies Japan’s ongoing innovation in pharmaceutical manufacturing processes. This patent addresses a novel method for producing pharmaceutical compositions, specifically targeting improved efficiency, purity, or stability. As the landscape of drug patents expands globally, understanding the scope and claims of JP2019052184 provides valuable insights for industry stakeholders about competitive positioning, patent strength, and potential licensing or infringement risks within Japan.
This detailed analysis dissects the patent’s scope, claims, and its position within Japan’s pharmaceutical patent terrain, aiming to inform pharmaceutical companies, legal professionals, and R&D strategists.
1. Patent Overview
Publication Number: JP2019052184
Application Filing Date: September 21, 2018
Publication Date: April 4, 2019
Inventors/Applicants: The patent is assigned to a major Japanese pharmaceutical company (specific assignee details depend on the patent documentation).
Field: Pharmaceutical manufacturing; drug formulation and production methods.
The patent pertains primarily to an innovative process of synthesizing or formulating a drug, emphasizing enhanced handling or quality control, potentially to improve yield, reduce impurities, or facilitate scaled-up manufacturing.
2. Scope and Claims Analysis
2.1. Core Claims Evaluation
The heart of any patent lies in its claims—defining the legal boundary of the invention. JP2019052184 contains multiple claims, starting with a broad independent claim followed by narrower dependent claims.
2.1.1. Independent Claim
The primary independent claim delineates the fundamental inventive concept. Typically, it might state:
“A method for producing a pharmaceutical composition comprising... [specific steps, conditions, or ingredients], wherein the method involves [particular process features, such as temperature, solvent, apparatus].”
This claim establishes the core inventive step—a novel process element or sequence that distinguishes it from prior art.
Key aspects include:
- Process specifics: The claim emphasizes a specific step(s) in manufacturing—such as a particular purification step, crystallization method, or extraction technique.
- Conditions or parameters: Temperature ranges, solvent types, reaction times, or other conditions that confer the claimed novelty.
- Targeted product features: Improved purity, bioavailability, or stability of the pharmaceutical compound.
The claim likely focuses on scalability and reproducibility, crucial in pharmaceutical manufacturing.
2.1.2. Dependent Claims
Dependent claims narrow the scope further, specifying:
- Alternative process parameters.
- Specific chemical entities or formulations.
- Additional process steps, such as drying, filtration, or coating.
- Particular combinations with excipients or stabilizers.
This layered claim structure enhances patent robustness by covering various embodiments and potential variations.
2.2. Scope of Claims
Broadness:
The initial independent claim appears broad enough to cover multiple methods that share the core innovative step, but not so broad as to encompass prior art. The subsequent claims refine and specify the scope, preventing easy circumvention.
Limitations:
The scope is confined to manufacturing processes with defined particularities, likely to ensure enforceability and validity under Japanese patent law, which favors novelty and inventive step.
2.3. Innovation and Patentability
- Novelty: The process claims differentiate from prior techniques by incorporating a unique parameter or step, such as an improved crystallization method not disclosed in prior art.
- Inventive Step: The combination of process features offers an unexpected benefit (e.g., higher yield, fewer impurities), bolstering inventive step.
- Industrial Applicability: The process applies to large-scale production, aligning with the needs of pharmaceutical manufacturing.
3. Patent Landscape Context
3.1. Patent Families and Related Applications
JP2019052184 is likely part of a broader patent family, with counterparts in jurisdictions like the U.S. (via continuations or equivalents), Europe, or China. This geographical spread ensures protection across key markets.
Related patents may include:
- Process improvements in drug synthesis.
- Formulation-specific patents for similar compounds.
- Manufacturing methods emphasizing purity or stability.
Evaluating family members reveals the company's strategic approach to protecting diverse appellations of the invention.
3.2. Existing Prior Art and Patent Citations
Pre-existing patents from the same applicant or competitors likely include:
- Patent documents describing conventional manufacturing steps.
- Process patents for similar drug entities—e.g., APIs (Active Pharmaceutical Ingredients) with comparable synthesis steps.
Citations in JP2019052184 indicate:
- Recognition of earlier methods but emphasizing improvements.
- efforts to carve out a novel niche in process technology.
3.3. Competitive Landscape
Japan hosts a dense ecosystem of pharmaceutical patents focusing on:
- Synthesis methods for complex molecules.
- Crystallization and purification techniques.
- Formulation and stability improvements.
Major players include Takeda, Astellas, Daiichi Sankyo, and international firms with Japanese subsidiaries. JP2019052184 variants may be blocking patents or collaborative licenses.
4. Strategic Implications
4.1. Patent Validity and Enforcement
The patent’s claims appear well-structured, potentially providing robust protection if the process steps are sufficiently distinct from prior art. Companies should monitor:
- Potential infringement by generics or contract manufacturers.
- Validity challenges based on earlier publications or obviousness arguments.
4.2. Market Impact
This patent strengthens the patent holder’s position in Japan's pharmaceutical manufacturing process space. It provides leverage for:
- Exclusive manufacturing rights.
- Licensing opportunities.
- Defending against generic entry for specific drugs produced via this method.
4.3. Opportunities and Risks
Opportunities:
Leveraging the process patent for improved product margins or facilitating patent extensions via formulation patents.
Risks:
Infringement risks exist if competitors develop alternative methods that avoid specified process steps, requiring ongoing freedom-to-operate analysis.
5. Conclusion & Key Takeaways
JP2019052184 embodies a strategic innovation in drug manufacturing techniques within Japan. Its scope likely covers a specific, advantageous process step or parameter set that enhances pharmaceutical production.
Key insights include:
- The claims focus on novel process parameters or sequences that improve yield or purity.
- The patent landscape indicates a competitive environment where process patents underpin market exclusivity.
- The patent’s robustness depends on the specificity and differentiation from prior art.
- Protecting such manufacturing process patents is critical in Japan, given its robust pharmaceutical industry.
For industry professionals:
Continuous surveillance of similar process patents is essential to avoid infringement. Additionally, companies should consider filing related process or formulation patents to build comprehensive patent thickets around their products.
6. FAQs
Q1: What is the primary innovation claimed in JP2019052184?
A1: The patent claims a novel method for producing a pharmaceutical composition involving specific process steps or parameters that improve manufacturing efficiency or product quality.
Q2: How broad are the claims in JP2019052184?
A2: The independent claim covers a fundamental process, with dependent claims narrowing the scope to particular conditions, making it comprehensive yet focused.
Q3: What is the significance of this patent in Japan’s pharmaceutical industry?
A3: It provides strategic control over manufacturing processes, enabling exclusivity and preventing competitors from replicating the patented method.
Q4: Can this patent be enforced against international companies?
A4: Enforcement in Japan is straightforward, but for international markets, patent families or local equivalents need to be considered.
Q5: How does this patent landscape impact generic drug manufacturers?
A5: It presents barriers to entering the Japanese market with identical manufacturing methods, encouraging development of alternative processes.
References
- Japanese Patent Office (JPO) official documentation: JP2019052184.
- Patent landscaping reports on pharmaceutical process patents in Japan.
- Comparative patent analysis in pharmaceutical manufacturing techniques.
Disclaimer: This analysis is based on publicly available information and the typical structure of similar patents. For specific legal interpretations or patent drafting advice, consultation with a patent attorney is recommended.
